Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals)
- J Med Chem. 2018 Jan 25;61(2):482-491. doi: 10.1021/acs.jmedchem.6b01872.
- 1. Institute of Pharmaceutical Sciences, University of Freiburg , Albertstraße 25, 79104 Freiburg im Breisgau, Germany.
- 2. Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences , Magyar Tudósok körútja 2, H 1117 Budapest, Hungary.
- 3. Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg , Wolfgang-Langenbeck-Straße 4, 06120 Halle (Saale), Germany.
- 4. Freiburg Institute of Advanced Studies (FRIAS), University of Freiburg , Albertstraße 19, 79104 Freiburg im Breisgau, Germany.
Here we report the development of a proteolysis targeting chimera (PROTAC) based on the combination of the unique features of the Sirtuin rearranging ligands (SirReals) as highly potent and isotype-selective SIRT2 inhibitors with thalidomide, a bona fide Cereblon Ligand. For the first time, we report the formation of a PROTAC by Cu(I)-catalyzed cycloaddition of a thalidomide-derived azide to an alkynylated inhibitor. This thalidomide-derived azide as well as the highly versatile linking strategy can be readily adapted to alkynylated ligands of Other targets. In HeLa cells, our SirReal-based PROTAC induced isotype-selective SIRT2 degradation that results in the hyperacetylation of the microtubule network coupled with enhanced process elongation. Thus, our SirReal-based PROTAC is the first example of a probe that is able to chemically induce the degradation of an epigenetic eraser protein.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: PROTAC LinkersResearch Areas: Cancer
-
-
Research Areas: Others
-
Research Areas: Cancer
-
target: PROTAC LinkersResearch Areas: Others
-
Research Areas: Others
-
Research Areas: Cancer
-
Research Areas: Cancer